We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

By
Simply Wall St
Published
May 11, 2022
NasdaqCM:NURO
Source: Shutterstock

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?

So should NeuroMetrix (NASDAQ:NURO) shareholders be worried about its cash burn? For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

Check out our latest analysis for NeuroMetrix

When Might NeuroMetrix Run Out Of Money?

You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. When NeuroMetrix last reported its balance sheet in March 2022, it had zero debt and cash worth US$24m. Importantly, its cash burn was US$2.9m over the trailing twelve months. So it had a cash runway of about 8.2 years from March 2022. Even though this is but one measure of the company's cash burn, the thought of such a long cash runway warms our bellies in a comforting way. The image below shows how its cash balance has been changing over the last few years.

debt-equity-history-analysis
NasdaqCM:NURO Debt to Equity History May 11th 2022

How Well Is NeuroMetrix Growing?

Notably, NeuroMetrix actually ramped up its cash burn very hard and fast in the last year, by 113%, signifying heavy investment in the business. While operating revenue was up over the same period, the 14% gain gives us scant comfort. Considering both these metrics, we're a little concerned about how the company is developing. In reality, this article only makes a short study of the company's growth data. This graph of historic earnings and revenue shows how NeuroMetrix is building its business over time.

How Easily Can NeuroMetrix Raise Cash?

While NeuroMetrix seems to be in a fairly good position, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Companies can raise capital through either debt or equity. Many companies end up issuing new shares to fund future growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Since it has a market capitalisation of US$21m, NeuroMetrix's US$2.9m in cash burn equates to about 14% of its market value. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.

Is NeuroMetrix's Cash Burn A Worry?

Even though its increasing cash burn makes us a little nervous, we are compelled to mention that we thought NeuroMetrix's cash runway was relatively promising. Cash burning companies are always on the riskier side of things, but after considering all of the factors discussed in this short piece, we're not too worried about its rate of cash burn. On another note, NeuroMetrix has 3 warning signs (and 1 which is potentially serious) we think you should know about.

Of course NeuroMetrix may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.